China Approves Desidustat Tablets for Renal Anemia, Addressing Critical Treatment Gap in CKD Patients
核心洞察
China's NMPA approved Desidustat Tablets on March 13, 2026, marking the first oral HIF-PHI (搜索) treatment for renal anemia in non-dialysis chronic kidney disease patients.
Phase III clinical trials demonstrated Desidustat's superior efficacy over placebo in increasing hemoglobin levels, with extension studies showing sustained target range maintenance and acceptable safety.
The approval addresses a significant unmet medical need, as only 8.2% of non-dialysis CKD anemia patients currently achieve target hemoglobin levels compared to 51.5% of hemodialysis patients.
China Medical System Holdings Limited (搜索) announced that the National Medical Products Administration of the People's Republic of China (NMPA) approved Desidustat Tablets for marketing on March 13, 2026. The novel oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI (搜索)) represents a significant advancement in treating anemia in non-dialysis adult chronic kidney disease (CKD) patients.
The approval addresses a critical treatment gap in China's healthcare system, where more than 120 million people suffer from CKD. Anemia prevalence increases dramatically with disease progression, affecting 22.0% of stage 1 CKD patients and reaching 98.2% in stage 5 patients. Currently, only 8.2% of non-dialysis CKD anemia patients achieve target hemoglobin levels of 110-120g/L, compared to 51.5% of hemodialysis patients.
Novel Mechanism Shows Clinical Promise
Desidustat operates through a unique mechanism of action that promotes erythropoiesis by increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin levels. China's Phase III clinical trial demonstrated positive results, with the primary endpoint showing Desidustat's superior efficacy over placebo in increasing hemoglobin levels from baseline to weeks 7-9.
Extension study results revealed the drug's ability to maintain hemoglobin levels within the target range over extended periods while demonstrating acceptable safety profiles. Additionally, Desidustat significantly reduces hepcidin levels and ameliorates iron metabolism disorders, addressing multiple pathways involved in CKD-related anemia.
Strategic Market Positioning
The approval strengthens China Medical System's nephrology portfolio, creating synergies with its marketed drug Velphoro (Sucroferric Oxyhydroxide Chewable Tablets) for CKD hyperphosphatemia. The company expects to leverage its established nephrology expert resources and channel networks to rapidly promote large-scale clinical application of Desidustat Tablets.
China Medical System obtained exclusive licensing rights for Desidustat from Zydus Lifesciences Limited through a license agreement effective January 20, 2020. The drug has previously received marketing approval in India, providing additional validation for its therapeutic potential.
Oral Administration Advantage
The oral formulation of Desidustat represents a significant advantage over traditional treatments, potentially improving patient compliance and meeting unmet treatment needs in CKD anemia management. This convenience factor could prove crucial in addressing the substantial treatment gap, particularly among non-dialysis patients who currently have limited effective therapeutic options.
Company Innovation Pipeline
The Desidustat approval adds to China Medical System's robust innovation portfolio, which includes seven approved new drugs, six products under marketing review, and nearly 20 projects in various stages of clinical development. The company's dual-engine innovation approach combines collaborative development with in-house R&D, focusing on first-in-class and best-in-class products across cardiovascular-kidney-metabolic, gastroenterology, ophthalmology, and skin health therapeutic areas.